MedTrace Logo

Evaluation of the Use of Empagliflozin in Patients with HF with PEF in a Cardiology Outpatient Department

NCT06683053 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2024-11-12

No results posted yet for this study

Summary

This study aims to evaluate whether the use of a 25 mg dose of empagliflozin compared to the 10 mg dose used would bring additional benefits in the improvement outcomes of the Kansas City Cardiomyopathy Questionnaire (KCCQ SST), in the 6-minute walk test (6MWT) without causing significant side effects.

Conditions

  • Congestive Heart Failure (CHF)

Interventions

DRUG

empagliflozin

Comparing the benefits of both doses of empagliflozin (10 mg versus 25 mg) in terms of heart ejection fraction and quality of life.

Sponsors & Collaborators

  • Conrado Roberto Hoffmann Filho

    lead NETWORK

Principal Investigators

  • Conrado R Hoffmann Filho, Doctor · Multidisciplinary Center for Specialized Education and Research Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-17
Primary Completion
2024-04-29
Completion
2025-02-28

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06683053 on ClinicalTrials.gov